Grimes & Company’s Oragenics OGEN Stock Holding History

Grimes & Company’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7	Closed	-$3K	–	304
2022 Q3	$3K	Buy	+7	New	+$4.09K	﹤0.01%	271

Other funds holding OGEN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBF

Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Grimes & Company's OGEN Position: Q4 2022 in Review

Grimes & Company sold out of Oragenics (OGEN) in Q4 2022, closing a stake of 7 shares — an estimated $3K sold.

Grimes & Company first reported a position in OGEN in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 24 funds tracked by Wall St. Rank hold OGEN as of Q4 2022.

Grimes & Company reported no remaining Oragenics position as of Q4 2022 after selling out during the quarter.
Grimes & Company sold 7 Oragenics shares in Q4 2022, an estimated $3K.
Grimes & Company first reported a position in Oragenics in Q3 2022 and held it in 1 quarter.
Grimes & Company's Oragenics position peaked at $3K in Q3 2022.
24 funds tracked by Wall St. Rank held Oragenics as of Q4 2022.

Based on Grimes & Company's 13F filing for Q4 2022, filed 25 Jan 2023.